Expand ZYME Menu
ZYME MENU

ZYME Latest Press Releases

-- January 12, 2026 --

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy Globe Newswire 6:00 AM

-- January 11, 2026 --

Zymeworks Outlines Strategic Priorities and Outlook for 2026 Globe Newswire 6:00 PM

-- January 6, 2026 --

Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit Globe Newswire 1:34 PM

-- December 2, 2025 --

Zymeworks Announces Participation in Upcoming Conferences Globe Newswire 4:05 PM

-- November 18, 2025 --

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 Globe Newswire 8:45 AM
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer Globe Newswire 1:01 AM
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets Globe Newswire 1:00 AM

-- November 17, 2025 --

Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open Globe Newswire 10:48 AM
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma Globe Newswire 6:00 AM

-- November 6, 2025 --

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results Globe Newswire 4:05 PM

-- October 28, 2025 --

Zymeworks Announces Participation in Upcoming Investor Conferences Globe Newswire 6:00 AM

-- October 23, 2025 --

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-? at AACR-NCI-EORTC Conference Globe Newswire 12:30 PM

-- October 16, 2025 --

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 Globe Newswire 6:00 AM

-- October 13, 2025 --

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International Conference Globe Newswire 4:00 PM

-- October 9, 2025 --

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer Globe Newswire 6:00 AM

-- September 2, 2025 --

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager Globe Newswire 6:00 AM
Market Data Delayed 15 Minutes